Association between immune-related adverse events and clinical outcomes for head and neck squamous cell carcinoma treated with first-line palliative pembrolizumab monotherapy or in combination with chemotherapy: a national, multi-centre, real-world, retrospective cohort study https://www.medrxiv.org/content/10.1101/2023.06.08.23290541